Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial

The Lancet. Respiratory Medicine
Birahim P NdiayeMVA85A 030 trial investigators

Abstract

HIV-1 infection is associated with increased risk of tuberculosis and a safe and effective vaccine would assist control measures. We assessed the safety, immunogenicity, and efficacy of a candidate tuberculosis vaccine, modified vaccinia virus Ankara expressing antigen 85A (MVA85A), in adults infected with HIV-1. We did a randomised, double-blind, placebo-controlled, phase 2 trial of MVA85A in adults infected with HIV-1, at two clinical sites, in Cape Town, South Africa and Dakar, Senegal. Eligible participants were aged 18-50 years, had no evidence of active tuberculosis, and had baseline CD4 counts greater than 350 cells per μL if they had never received antiretroviral therapy or greater than 300 cells per μL (and with undetectable viral load before randomisation) if they were receiving antiretroviral therapy; participants with latent tuberculosis infection were eligible if they had completed at least 5 months of isoniazid preventive therapy, unless they had completed treatment for tuberculosis disease within 3 years before randomisation. Participants were randomly assigned (1:1) in blocks of four by randomly generated sequence to receive two intradermal injections of either MVA85A or placebo. Randomisation was stratified by ...Continue Reading

References

Dec 1, 1993·International Journal of Epidemiology·L C RodriguesJ G Wheeler
Mar 2, 1994·JAMA : the Journal of the American Medical Association·G A ColditzF Mosteller
Jun 28, 2008·The Journal of Infectious Diseases·Tony HawkridgeHelen McShane
Jan 20, 2009·American Journal of Respiratory and Critical Care Medicine·Clare R SanderHelen McShane
Jun 3, 2009·Infection and Immunity·H Martin VordermeierR Glyn Hewinson
Jul 2, 2011·The European Respiratory Journal·M X RangakaR J Wilkinson
Mar 28, 2012·Tuberculosis·Michael J Brennan, Jelle Thole
May 9, 2013·Future Virology·Naomi F WalkerRobert J Wilkinson
Dec 11, 2013·The Lancet. Respiratory Medicine·Dennis FalzonMario C Raviglione
Dec 18, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Punam MangtaniJonathan A Sterne
Mar 29, 2014·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·H CoxG van Cutsem
Nov 28, 2014·Microbiology and Molecular Biology Reviews : MMBR·Thomas R HawnSteven G Self

❮ Previous
Next ❯

Citations

Nov 13, 2015·Human Vaccines & Immunotherapeutics·Helen McShane
Jan 27, 2016·Human Vaccines & Immunotherapeutics·Matthew K O'Shea, Helen McShane
Jul 1, 2015·Human Vaccines & Immunotherapeutics·A J Graves, D A Hokey
Mar 24, 2016·Human Vaccines & Immunotherapeutics·Yu PangSuhua Zheng
Mar 11, 2016·Pathogens and Disease·Hazel M Dockrell
Mar 3, 2015·The Lancet. Respiratory Medicine·Martin RaoMarkus Maeurer
Apr 26, 2016·The Journal of Clinical Investigation·Andreas KupzStefan H E Kaufmann
Apr 15, 2016·Expert Review of Vaccines·Alberto L García-BasteiroChristoph Lange
May 14, 2016·International Journal of Epidemiology·Pcl Beverley
May 21, 2016·Future Microbiology·Helen A Fletcher, Hazel M Dockrell
Jul 30, 2016·Tuberculosis·Ann M GinsbergHelen McShane
Feb 6, 2016·Expert Opinion on Emerging Drugs·S HofmanJ W C Alffenaar
Jun 16, 2017·Cell Host & Microbe·Albanus O MogucheKevin B Urdahl
Jun 14, 2017·Expert Review of Vaccines·Stefan H E KaufmannJeroen Maertzdorf
Nov 22, 2017·Proceedings of the National Academy of Sciences of the United States of America·Andrew ChancellorSalah Mansour
Aug 7, 2018·Current Opinion in HIV and AIDS·Elisa NemesMark Hatherill
Oct 14, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Elisa NemesUNKNOWN MVA029 Study Team
Feb 6, 2019·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Bastiaan A BlokMihai G Netea
Feb 23, 2019·Expert Review of Vaccines·Claudio CounoupasWarwick J Britton
Mar 21, 2019·Expert Review of Vaccines·Ann M Ginsberg
Nov 27, 2018·Current Molecular Pharmacology·Manaf AlMatarFatih Köksal
Dec 5, 2015·Clinical Medicine : Journal of the Royal College of Physicians of London·Neesha Rockwood, Robert John Wilkinson
Dec 27, 2019·Expert Review of Vaccines·Elena StylianouHelen McShane
Oct 29, 2019·American Journal of Respiratory and Critical Care Medicine·Liku B TezeraPaul Elkington
May 1, 2019·The Cochrane Database of Systematic Reviews·Rufaro KashanguraSamuel Johnson
Jan 8, 2020·Proceedings of the National Academy of Sciences of the United States of America·Ahmet OzdilekFikri Y Avci

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA

Clinical Trials Mentioned

NCT01151189

Software Mentioned

Aeras

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.